维生素D水平对慢性乙型肝炎抗病毒疗效的预测价值

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the predictive value of baseline vitamin D level on the virological response of chronic hepatitis B.Methods A total of 115 inpatients with chronic hepatitis B from October 2017 to December 2019 in the Third People′s Hospital of Shenzhen were included.According to the hepatitis B virus DNA quantitative analysis at treatment week 24,patients were divided into HBV DNA-negative group and HBV DNA-positive group.The clinical baseline characteristics of the two groups were compared.Predictive models were established using multivariate Logistic regression analyses,with the receiver operating characteristic(ROC)curve and the Hosmer-Lemeshow goodness of fit test employed as the evaluation indicators.Results Antiviral treatment for 24 weeks,71 cases(61.74%)and 44 cases(38.26%)were HBV DNA-negative and HBV DNA-positive respectively.With lower HBV DNA level and higher vitamin D level,the 24-week virological outcomes were better(P＜0.05).HBV DNA level and alanine aminotransferase were included in model 1,and HBV DNA level,HBsAg level,total bilirubin,and 25-hydroxy vitamin D were included in model 2.The areas under the ROC curve(AUC)of model 1 and model 2 were 0.735(95%CI:0.639-0.831)and 0.810(95%CI:0.732-0.890)respectively.The AUC of the two models was compared,and the difference was statistically significant(P=0.039).Conclusion The predictive model based on the baseline vitamin D level has a good predictive value for the 24-week virological response in the treatment of chronic hepatitis B.

Key words： Vitamin D 25-hydroxy vitamin D Chronic hepatitis B Predictive model

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Xuan
	ZHANG Li-na
	WANG Song
	WANG Fang
	HE Qing

Cite this article:

LI Xuan,ZHANG Li-na,WANG Song, et al. Predictive value of vitamin D level on antiviral efficacy of chronic hepatitis B[J]. 中国当代医药, 2021, 28(15): 12-15.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I15/12

[1]	Aziz M，Aziz H，Waheed Y，et al.Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients[J].Viral Immunol，2018，31（9）：632-638.
[2]	Zeuzem S，Gane E，Liaw YF，et al.Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B[J].J Hepatol，2009，51（1）：11-20.
[3]	Martens PJ，Gysemans C，Verstuyf A，et al.Vitamin D′s Effect on Immune Function[J].Nutrients，2020，12（5）：1248.
[4]	Kim GA，Lim YS，Han S，et al.High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J].Gut，2018，67（5）：945-952.
[5]	Chang Y，Choe WH，Sinn DH，et al.Nucleos（t）ide Analogue Treatment for Patients With Hepatitis B Virus（HBV）e Antigen-Positive Chronic HBV Genotype C Infection：A Nationwide，Multicenter，Retrospective Study[J].J Infect Dis，2017，216（11）：1407-1414.
[6]	张原青，彭利军，曹忆嵘，等.慢性乙型肝炎肝硬化患者发生肝细胞癌的危险因素分析[J].中华肝脏病杂志，2015（7）：512-516.
[7]	Tang A，Hallouch O，Chernyak V，et al.Epidemiology of hepatocellular carcinoma：target population for surveillance and diagnosis[J].Abdom Radiol（NY），2018，43（1）：13-25.
[8]	王贵强，段钟平，王福生，等.慢性乙型肝炎防治指南（2019年版）[J].实用肝脏病杂志，2020，23（1）：9-32.
[9]	Cho JY，Sohn W，Sinn DH，et al.Long-term real-world entecavir therapy in treatment-nave hepatitis B patients：baseline hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response[J].Korean J Intern Med，2017，32（4）：636-646.
[10]	Dobson R，Giovannoni G.Multiple sclerosis-a review[J].Eur J Neurol，2019，26（1）：27-40.
[14]	李冰，黄辉红，江自成，等.血清维生素D水平对慢性乙型肝炎患者抗病毒疗效的影响[J].肝脏，2018，23（10）：895-897.
[11]	Ye B，Liu X，Li X，et al.T-cell exhaustion in chronic hepatitis B infection：current knowledge and clinical significance[J].Cell Death Dis，2015，6（3）：e1694.
[12]	Li TY，Yang Y，Zh ou G，et al.Immune suppression in chronic hepatitis B infection associated liver disease：A review[J].World J Gastroenterol，2019，25（27）：3527-3537.
[13]	He LJ，Zhang HP，Li HJ，et al.Effect of Serum Vitamin D Levels on Cellular Immunity and Antiviral Effects in Chronic Hepatitis B Patients[J].Clin Lab，2016，62（10）：1933-1939.
[15]	Gal-Tanamy M，Bachmetov L，Ravid A，et al.Vitamin D：an innate antiviral agent suppressing hepatitis C virus in human hepatocytes[J].Hepatology，2011，54（5）：1570-1579.
[16]	Matsumura T，Kato T，Sugiyama N，et al.25-Hydroxyvitamin D3suppresses hepatitis C virus production[J].Hepatology，2012，56（4）：1231-1239.
[17]	Bi Y，Zhang W，Sun J，et al.Therapeutic and immune function improvement of vitamin D combined with IFN-α on mouse with hepatitis B infection[J].Int J Immunopathol Pharmacol，2018，32：2058738418775250.
[18]	Sheppard-Law S，Zablotska-Manos I，Kermeen M，et al.Factors associated with non-adherence to HBV antiviral therapy[J].Antivir Ther，2018，23（5）：425-433.